Abstract
Acute renal failure (ARF) represents a severe complication of malignancies, that causes significant morbidity and mortality. ARF is a common part of multiple organ dysfunction in critically ill patients with cancer with reported mortality rates from 72% to 85% in patients who need renal replacement therapy. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, certain factors leading to the development of ARF may be associated to the tumor or to the tumor therapy. The purpose of this review is to give specific aspects of renal disease in critically ill cancer patients (CICPs), to overview the causes of ARF in CICPs and to describe recent progress in the management of these complications, including treatment toxicity and bone marrow transplantation (BMT). The prevention of ARF is obligatory and therefore the possible treatments of ARF in CICPs are also discussed.
Keywords: Acute renal failure, tumor lysis syndrome, hepatocellular carcinoma (HCC), multiple myeloma, lymphoma.
Current Medicinal Chemistry
Title:Acute Renal Failure in Different Malignant Tumors
Volume: 23 Issue: 19
Author(s): Sanja Radojevic-Skodric, Ljiljana Bogdanovic, Milena Jovanovic, Ivana Baralic, Zoran Dzamic, Ron Gordon, Simona Ognjanovic and Gordana Basta-Jovanovic
Affiliation:
Keywords: Acute renal failure, tumor lysis syndrome, hepatocellular carcinoma (HCC), multiple myeloma, lymphoma.
Abstract: Acute renal failure (ARF) represents a severe complication of malignancies, that causes significant morbidity and mortality. ARF is a common part of multiple organ dysfunction in critically ill patients with cancer with reported mortality rates from 72% to 85% in patients who need renal replacement therapy. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, certain factors leading to the development of ARF may be associated to the tumor or to the tumor therapy. The purpose of this review is to give specific aspects of renal disease in critically ill cancer patients (CICPs), to overview the causes of ARF in CICPs and to describe recent progress in the management of these complications, including treatment toxicity and bone marrow transplantation (BMT). The prevention of ARF is obligatory and therefore the possible treatments of ARF in CICPs are also discussed.
Export Options
About this article
Cite this article as:
Radojevic-Skodric Sanja, Bogdanovic Ljiljana, Jovanovic Milena, Baralic Ivana, Dzamic Zoran, Gordon Ron, Ognjanovic Simona and Basta-Jovanovic Gordana, Acute Renal Failure in Different Malignant Tumors, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/0929867323666160407113245
DOI https://dx.doi.org/10.2174/0929867323666160407113245 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic Activities
Anti-Cancer Agents in Medicinal Chemistry Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors
Current Medicinal Chemistry - Anti-Infective Agents VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism Autophagy in Diabetic Retinopathy
Current Neuropharmacology Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Post-Translational Control of Sp-Family Transcription Factors
Current Genomics Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine